Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 24.0 | 97 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 27.0 | 84 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 26.0 | 69 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 33.0 | 73 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 26.0 | 68 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 27.5 | 78 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 153.0 | 65 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 272.5 | 84 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 96.5 | 82 | |
N2759 | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 96.0 | 78 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 340.0 | 67 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 420.0 | 85 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 187.5 | 46 | |
N2586 | IL-1 alpha | 100 | ng/mL | 1 | MCP3 | 175.0 | 32 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 20.0 | 49 | |
RA1869 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 20.0 | 64 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 18.0 | 72 | |
N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 17.0 | 71 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 15.0 | 97 | |
RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 18.5 | 72 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 19.0 | 60 | |
N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 20.0 | 71 | |
RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 49.0 | 57 | |
RA1869 | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 86.5 | 44 | ||||
N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 1 | MCP3 | 21.5 | 60 |